Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Target group-oriented information more effective in the prevention of skin cancer Avoid sunburn. This is the main advice for the prevention of skin cancer. Targeted information is needed to ensure that people adapt their behaviour accordingly. In places where people are exposed to the sun, for example, or for certain groups of peo
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
New: NEVO online 2021 RIVM published a new online edition of the Dutch food composition database (NEVO).
The National Immunisation Programme: the number of disease notifications decreased substantially in 2020 In 2020, fewer people fell ill from a disease against which vaccination is included in the National Immunisation Programme than in 2019. This is most likely due to coronavirus measures, such as social distancing, handwashing, and travel restrictions.
Vaccination coverage increases for second consecutive year, by 10% for HPV The percentage of children receiving vaccinations from the National Immunisation Programme rose again last year. Another striking note is the 10% increase in HPV vaccination, rising to 63%.
Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.